English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Aim: To compare the anti-inflammatory effects of Metformin sulfonylurea and Sitagliptin combination with Metformin Sulfonylurea and Acarbose combination in Type2DM patients by using Anti-inflammatory markers (IL6, hs CRP) and also To compare the clinical outcome between these two groups by using the following parameters FBS, PPBs, HbA1C, Plasma Insulin. Materials and Method : In this study 30 type 2 diabetes patients on Metformin and Sulfonylurea combination ,HbA1c value >7.5 were recruited and randomized into two groups in which one group was added on Acarbose and the other group was added with Sitagliptin along with Metformin, Sulfonylurea combinations and followed for 3 months. Result : In this study Sitagliptin combination reduced the mean value of FBS, PPBS, HbA1c, Plasma Insulin , Insulin Resistance ,hsCRP and IL-6 , which were similar to the results of previous studies. In Acarbose combination, there was a reduction in the mean values of FBS,PPBS, HbA1c, Plasma Insulin, Insulin Resistance, hsCRP but not IL-6. Hence long term follow up and large sample size may be required to see the progression in the reduction of inflammatory markers and the role of these drugs in the insulin resistant states. Conclusion : This study explained the synergism when Sitagliptin given along with Metformin Sulfonylurea combination and has proved a definite role in reducing chronic inflammation.

To Compare the Anti-Inflammatory Effect of Oral Hypoglycemic Drugs in Type 2 Diabetes Mellitus